Want to see IRTC full AI Analyst Report?
IRTC Stock Chart & Stats
$123.09
$1.53(1.42%)
At close: 4:00 PM EDT
$123.09
$1.53(1.42%)
Day’s Range― - ―
52-Week Range$100.70 - $212.00
Previous CloseN/A
Volume317.85K
Average Volume (3M)503.01K
Market Cap
$3.61B
Enterprise Value$4.05B
Total Cash (Recent Filing)$591.27M
Total Debt (Recent Filing)$727.35M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Nov 05, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding32,963,000
10 Day Avg. Volume479,858
30 Day Avg. Volume503,006
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue4.91
Enterprise Value/Gross Profit6.87
Enterprise Value/Ebitda150.76
Forecast
1Y Price Target
$173.36Price Target Upside40.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$890.60M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthStrong recent growth and raised full-year guidance indicate expanding utilization of iRhythm’s monitoring platform and effective commercial execution. Sustained top-line momentum can support operating leverage, broaden the customer base, and reinforce the company’s position in ambulatory cardiac monitoring.
VitalConnect Platform ExpansionThe completed VitalConnect acquisition expands iRhythm beyond its existing monitoring offerings and adds capabilities across ambulatory, inpatient and hospital-to-home workflows. A broader product suite can increase addressable market, deepen health-system relationships, and create additional cross-selling opportunities.
Technology-Driven Margin OpportunityAutomating more of the clinical review process could lower service-delivery costs while preserving the value of iRhythm’s data and reporting platform. The expected efficiency gains provide a durable path to higher margins and greater capacity as monitoring volumes grow.
Bears Say
High Financial LeverageThe debt-heavy capital structure reduces financial flexibility and leaves less capacity to absorb operating setbacks or fund additional expansion internally. Higher leverage also creates refinancing and interest-cost exposure, making execution and sustained cash generation more important over the coming quarters.
Profitability And Free Cash Flow Not Yet ConsistentAlthough adjusted results and EBITDA have improved, negative TTM net income and modest, declining free cash flow show that the earnings improvement is not yet fully established on a GAAP or cash basis. Continued investment or working-capital volatility could delay durable self-funded growth.
Outstanding FDA Warning LetterThe unresolved FDA warning letter remains a regulatory overhang that could require further remediation, management attention, or operational changes. Uncertainty around agency closure may complicate product planning and customer confidence until the matter is formally resolved.
Irhythm Technologies News
IRTC FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest stock price was $100.70 and its highest was $212.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $3.61B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Nov 05, 2026 which is in 16 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Aug 06, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.03.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is 0.02.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,963,000 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -0.219%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in IRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$173.36 (40.84% Upside)
$173.36 (40.84% Upside)
Blogger Sentiment
Bullish
IRTC Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 88.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.71%
12-Months-Change
Fundamentals
Return on Equity
-8.97%
Trailing 12-Months
Asset Growth
13.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Irhythm Technologies
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
IRTC Company Deck
IRTC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: high‑teens to low‑20% organic revenue growth, record profitability and free cash flow, raised guidance, constructive reimbursement news, and a strategic acquisition (VitalConnect) that expands modality, market opportunity and multivital capabilities. Notable risks discussed include an outstanding FDA warning letter, a recent cybersecurity incident, a $50 million litigation settlement, integration and regulatory review risks related to the VitalConnect acquisition, and the pending clearance of the company’s Zio MCT product. On balance, positive execution, margin expansion, and clear strategic rationale for the acquisition outweigh the manageable regulatory and integration headwinds.View all IRTC earnings summariesIRTC Stock 12 Month Forecast
Average Price Target
$173.36
▲(40.84% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Koninklijke Philips
―
Medtronic
―
GE Healthcare Technologies Inc
―
Ownership Overview
2.02% Insiders
31.15% Mutual Funds
0.18% Other Institutional Investors
50.95% Public Companies and
Individual Investors